Neurology Clinical Trials Market- Growth, Share, Opportunities & Competitive Analysis, 2024 – 2032

Market Overview:

The Neurology Clinical Trials Market was valued at USD 6,412 million in 2024 and is projected to reach USD 10,611.83 million by 2032, growing at a compound annual growth rate (CAGR) of 6.5% during the forecast period (2024-2032).

The growth of this market is primarily driven by the increasing prevalence of neurological disorders worldwide, advancements in treatment options, and the rising demand for innovative therapies. With an aging global population, the incidence of neurological diseases is increasing, driving the need for more effective interventions. Additionally, the growing focus on healthcare awareness and early diagnosis is fueling market demand. Breakthroughs in gene therapy, biologics, and personalized medicine are enhancing the scope of clinical trials in neurology. The development of more targeted therapies for diseases such as Alzheimer’s and Parkinson’s is significantly boosting clinical research. Furthermore, government initiatives and funding aimed at expanding research in the field, coupled with collaborative efforts between public and private sectors, are accelerating clinical trials in neurology. The involvement of key stakeholders, including biotechnology firms, academic institutions, and healthcare providers, is also a major factor fueling market growth.

Market Drivers:

Advancements in Neurological Treatments:

Significant advancements in treatment options for neurological disorders are driving the expansion of the neurology clinical trials market. Innovative therapies such as biologics, gene therapies, and personalized medicine are opening new avenues for treating complex neurological conditions. For example, researchers at NYU Langone have developed remotely supervised transcranial direct current stimulation (RS-tDCS) to relieve symptoms associated with multiple sclerosis (MS). The development of targeted treatments addressing the specific genetic and molecular factors of diseases like Alzheimer’s and Parkinson’s is enhancing the effectiveness of clinical trials. As these new therapies promise improved outcomes, the demand for clinical trials to test these treatments continues to rise, further contributing to market growth.

Market Challenges:

Recruitment and Retention of Patients:

A major challenge in the neurology clinical trials market is the recruitment and retention of patients. Neurological disorders often affect complex and diverse patient populations, making it difficult to identify suitable candidates for trials. Many patients with conditions such as Alzheimer’s and Parkinson’s suffer from cognitive impairments or other health issues, making their participation in trials more challenging. Additionally, the long duration and demanding nature of clinical trials—particularly for neurodegenerative diseases—can lead to high dropout rates. Ensuring consistent patient engagement and retention throughout the trial is critical for obtaining reliable results, but it remains a significant hurdle for researchers and sponsors.

Segmentation:

By Phase:

Phase I

Phase II

Phase III

Phase IV

By Study Design:

Interventional

Expanded Access

Observational

By Indication:

Epilepsy

Huntington’s Disease

Stroke

Traumatic Brain Injury (TBI)

Amyotrophic Lateral Sclerosis (ALS)

Muscle Regeneration

Parkinson’s Disease

Other Indications

By Region:

North America: U.S., Canada, Mexico

Europe: Germany, France, U.K., Italy, Spain, Rest of Europe

Asia Pacific: China, Japan, India, South Korea, Southeast Asia, Rest of Asia Pacific

Latin America: Brazil, Argentina, Rest of Latin America

Middle East & Africa: GCC Countries, South Africa, Rest of the Middle East and Africa

Key Players:

Biogen

IQVIA

Novartis

Covance

Medpace

Charles River Laboratories

GlaxoSmithKline

Aurora Healthcare

Pfizer Inc.

Eli Lilly and Company